Gabapentin Tablet, Film Coated
Product Images NDC 60760-066

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 60760-066). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gaba (Gabapentin 60760 066 90)

Gabapentin 600 mg film-coated tablets, USP, in a package containing 90 tablets. Manufactured by M/s Strides Shasun Limited, India, and packaged by St. Mary's Medical Park Pharmacy, Oro Valley, AZ. The label includes instructions to use as directed and store at controlled room temperature (15°-30°C). The NDC is 60760-066-90.*

FDA Label Image

Figure 1 (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

An illustration showing the formula for estimating creatinine clearance (CLCr), which includes patient age in years, weight in kilograms, serum creatinine in mg/dL, and a female sex adjustment factor of 0.85.*

FDA Label Image

Chem Structure (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

Chemical structure diagram showing the molecular structure of gabapentin, the active ingredient in the medication Gabapentin 600 mg film-coated tablets, an oral prescription drug by St. Mary's Medical Park Pharmacy.*

FDA Label Image

Figure01 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

A line graph showing the mean pain score over an 8-week period for two groups: Placebo and Gabapentin 3600 mg/day. The x-axis represents weeks from baseline through week 8, with the first 4 weeks labeled as the dose titration period and the next 4 weeks as the fixed dose period. The y-axis shows mean pain scores ranging from 0 to 10. The Gabapentin group shows a decreasing trend in pain score, while the placebo group remains relatively stable.*

FDA Label Image

Figure02 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

A line graph showing mean pain scores over a 7-week period. It compares placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day during a 3-week dose titration period followed by a 4-week fixed dose period. The mean pain score decreases more for both Gabapentin doses compared to placebo over time.*

FDA Label Image

Figure03 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

A bar chart titled 'Figure 3. Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies.' It compares the percentage of responders across two studies. Study 1 shows 12% for PBO and 29% for GBP 3600. Study 2 shows 14% for PBO, 32% for GBP 1800, and 34% for GBP 2400. Statistical significance indicators are included above some bars.*

FDA Label Image

Figure4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

A scatter plot displaying the percentage difference versus daily dose in mg for Gabapentin in three studies labeled a, b, and c. The x-axis represents daily dose ranging from 600 to 1800 mg, and the y-axis shows percentage difference up to 22%. Data points are color-coded and marked by study, showing varying percentage differences with increasing dose.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.